Skip to content

Cash ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Merck & Co. logo
Merck & Co.MRK
0.2×-0.1×
United Therapeutics logo
United TherapeuticsUTHR
2.1×-0.5×
Rein Therapeutics, Inc. Common Stock logo
Rein Therapeutics, Inc. Common StockRNTX
0.3×-0.9×
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
3.2×+0.4×
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
1.3×-0.4×

Other financials

Income statement

See full
Revenue-
Operating income-$11.4M+27.5%
Net income-$10.8M+27.5%
EPS (diluted)-$0.11+35.3%

Balance sheet

See full
Cash & equivalents$10.0M-3.4%
Total debt$12.3M-9.2%
Total equity$57.9M-22.8%
Total assets$79.7M-18.1%

Cash flow

See full
Operating cash flow-$12.5M+18.8%
CapEx$138.0K
Free cash flow-$12.7M+17.9%

Valuation

See full
Market cap$1.14B+30.5%
Enterprise value$1.15B
P/S6,014.3×

Profitability

See full
Operating margin-40,856.3%+28,833pp
Net margin-39,009.5%+29,653pp
FCF margin-32,664.7%+4,018pp

Returns & leverage

See full
Return on equity-105.3%+50.6pp
Debt / equity0.2×0.0×
Current ratio5.8×-2.0×

Where this comes from

Calculated from Ethos Technologies, Inc. ’s reported figures.

Based on the most recent quarter.

The official record: Ethos Technologies, Inc. ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ethos Technologies, Inc. 's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ethos Technologies, Inc. 's cash ratio?
Ethos Technologies, Inc. (LIFE) reported cash ratio of 0.9× in Q1 2026.
How has Ethos Technologies, Inc. 's cash ratio changed year-over-year?
Ethos Technologies, Inc. 's cash ratio decreased by 11.8% year-over-year, from 1× to 0.9×.
What is the long-term trend for Ethos Technologies, Inc. 's cash ratio?
Over 5 years (2020 to 2025), Ethos Technologies, Inc. 's cash ratio has grown at a -24.5% compound annual growth rate (CAGR), from 2.9× to 0.7×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.